HealthDay News — More than 4 in 10 people older than 50 years (42%) have not gotten either a flu or COVID-19 vaccine, according to the results of a survey conducted by the University of Michigan ...

The plea from Oz, a cardiothoracic surgeon, was the most forceful yet for vaccination from an administration that has repeatedly expressed skepticism about vaccine safety and effectiveness. Measles ...

More patients receiving tenecteplase versus standard medical treatment had excellent functional outcome at 90 days.

One in four young people taking these medicines were prescribed other medications carrying a risk of serious drug interactions.

HealthDay News — Lowering the annual cost of semaglutide by 18% (from $8604 to $7055) or making the current cash price available to all patients would make semaglutide cost-effective, according to a ...

Of those with uncontrolled blood pressure, more than 6 in 10 are not taking antihypertensive medication. HealthDay News — Most US adults with uncontrolled blood pressure (BP) are not taking ...

Oveporexton is designed to promote wakefulness and reduce abnormal REM-sleep-like phenomena, including cataplexy, in patients with NT1.

The FDA is expected to decide on treatments for acquired hypothalamic obesity, dry eye disease, primary biliary cholangitis, psoriatic arthritis, and severe leukocyte adhesion deficiency-I.

HealthDay News — Hims & Hers says it will stop selling a low-cost copy of a new weight-loss pill made by Novo Nordisk, after federal officials raised concerns that the product may violate drug laws.

HealthDay News — For human papillomavirus (HPV) testing for detection of cervical intraepithelial neoplasia grade 2/3 or worse (CIN2+/CIN3+), minipad-collected menstrual blood shows comparable ...

HealthDay News — The US Food and Drug Administration (FDA) will now allow food labels to claim products have “no artificial colors” as long as they avoid petroleum-based dyes.

The table below is a review of notable updates that occurred in January 2026 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.